Wegovy label adds acute kidney injury warning tied to fluid loss

Wegovy's prescribing information now includes a warning about acute kidney injury caused by volume depletion, a change the label dates to August 2025 ^[1]. The label covers both the Wegovy injection and Wegovy tablets, which contain semaglutide ^[1].

What the label says

The Recent Major Changes list at the top of the Wegovy label records "Warnings and Precautions, Acute Kidney Injury due to Volume Depletion (5.5) ... 08/2025" ^[1]. In that section, the label directs prescribers to "Monitor renal function in patients reporting adverse reactions that could lead to volume depletion" ^[1].

A second entry on the same list, dated 10/2025, covers "Severe Gastrointestinal Adverse Reactions (5.6)" ^[1]. That section says Wegovy use "has been associated with gastrointestinal adverse reactions, sometimes severe," and that the drug is not recommended for patients with severe gastroparesis ^[1].

Read together, the two sections describe a sequence clinicians are being asked to watch: stomach and bowel side effects, loss of body fluid, and then strain on the kidneys. The kidney warning section does not say how many cases were reported, how those patients were affected, or which symptoms should prompt a kidney test ^[1].

Wegovy is a GLP-1 receptor agonist first approved in the United States in 2017 ^[1]. The injection is given once weekly, with a usual maintenance dose of 2.4 mg, and the tablets are taken once daily, with a recommended maintenance dose of 25 mg for cardiovascular risk reduction and weight reduction in adults ^[1]. The label lists indications for reducing cardiovascular risk in adults with established cardiovascular disease and either obesity or overweight, for weight reduction in adults and in children 12 and older with obesity, and, under accelerated approval, for noncirrhotic MASH with moderate to advanced liver fibrosis ^[1].

Other changes on the same list

The recent-changes list also shows that the section on suicidal behavior and ideation (5.10) was removed in 02/2026, that a warning about sharing the Wegovy FlexTouch pen between patients (5.11) was added in 06/2026, and that the Indications and Usage and Dosage and Administration sections were revised in 08/2025, 12/2025 and 03/2026 ^[1]. The boxed warning about thyroid C-cell tumors in rodents, and the contraindication for patients with a personal or family history of medullary thyroid carcinoma or MEN 2, remain in place ^[1].

Why it matters for patients

Nausea, vomiting and diarrhea are the gastrointestinal side effects the label flags, and they are the ones that can leave a person short on fluid ^[1]. The new warning tells doctors to check kidney function when a patient reports reactions that could cause that kind of fluid loss ^[1]. It does not address dosing, and it does not set a fluid intake target or name a lab schedule.

The label does not single out particular patient groups for extra monitoring. It ties the instruction to patients who report reactions that could lead to volume depletion, so the trigger is what a patient tells a clinician, not a diagnosis on file ^[1]. The gastrointestinal section separately says severe reactions can occur with use and that Wegovy is not recommended for people with severe gastroparesis ^[1].

Acute kidney injury from volume depletion is distinct from the label's other kidney-related content and sits alongside existing warnings for pancreatitis, gallbladder disease, hypoglycemia when used with insulin or an insulin secretagogue, and hypersensitivity reactions ^[1]. Whether the August 2025 addition changes how often kidney function is tested in practice has not been reported.

What happens next

The version of the Wegovy label carrying this warning was updated June 18, 2026, and includes changes dated through 06/2026 ^[1]. No further details about the kidney warning, such as case counts or follow-up requirements, have been disclosed in the labeling ^[1].